Bayer Aktiengesellschaft (BAYN) Earnings Call Transcript & Summary
August 5, 2021
Earnings Call Speaker Segments
Operator
operatorGood day, everyone, and thanks for holding. You're joined on Bayer's Investor and Analyst Conference Call covering the Q2 2021 results. During this recorded presentation today, everyone will be in listen-only mode. After the presentation, there will be a question and answer session. Should anyone have trouble hearing the conference, just press the star key, then zero, on your phone and an operator will assist you. At this point, I'll hand the conference to Mr. Oliver Maier, Head of Investor Relations at Bayer AG. Sir, the floor is yours.
Oliver Maier
executiveThank you, Emma. Good afternoon, everyone, and thanks for being with us today. I'd like to welcome all of you to the conference call for our Q2 2021. Joining me today are Werner Baumann, our CEO, and Wolfgang Nickl, our CFO. The businesses are represented by the responsible management board members. So with that, Werner will kick off today's call, as usual, with a summary of the key developments in Q2, and after that Wolfgang will walk through how our businesses performed and the outlook for 2021, and then we'll open up the Q&A session. As always, I want to begin today's call by pointing you to the cautionary language contained in our safe harbor statement, as well as in all the materials we've distributed today. With that, I'll hand things over to you, Werner.
Werner Baumann
executiveOkay. Thank you, Oliver, and good afternoon, everyone. I'm delighted to have you join our conference call today. At the start of the year, we committed to laying the groundwork for growth. We're truly pleased that, in fact, every one of our businesses delivered double-digit growth in Q2 on a currency- and portfolio-adjusted basis. That robust growth trajectory also comes through in the company's H1 2021 figures. Because of market swings caused by the pandemic and the seasonal pattern of our business, our year-to-date performance represents our underlying results and strong growth momentum better. In Crop Science, the favorable market conditions have kept commodity prices for corn and soybeans strong, which has driven a strong top-line development. In Pharma, Xarelto and Eylea, our blockbusters, maintained their growth momentum. We also observed a significant recovery overall in elective treatments, and our Consumer Health business carried on along its path of leading growth and margin improvement. For the rest of the year, we anticipate continued positive dynamics across all businesses, and therefore we are raising our guidance. It goes without saying that the pandemic and its related effects could bring further volatility, which requires close monitoring. Let me now turn to our objective of advancing our late-stage pipeline this year.
Werner Baumann
executiveThanks to our latest approvals, our new product pipeline now looks considerably de-risked. NUBEQA's rollout is continuing and keeps surpassing what we expected. We also moved forward with the launch of Verquvo, our new treatment for symptomatic chronic heart failure. After the FDA's January approval, we obtained market authorization in the European Union and Japan. Kerendia, which treats patients who have chronic kidney disease along with Type 2 diabetes, is the final addition to our launch products. The recent FDA approval gives patients a new route to protection against further kidney damage by tackling MR overactivation, a key driver behind chronic kidney disease progression that currently available therapies leave unaddressed. Strategically, it is also worth noting that we are now re-entering the U.S. market commercially in this indication with our own marketing and sales organization. I'm sure you also saw yesterday's good news about our eliapixant, our P2X3 receptor antagonist. The phase II-B study in chronic cough came back positive and demonstrated efficacy along with an excellent safety profile, which leaves us very optimistic about this new treatment option and about the running phase II trials in other indications that are underway. Let me now touch on some further highlights in our early programs and platforms.
Werner Baumann
executiveWe're seeing excellent momentum in our early-stage pipeline built around the cell and gene therapy platform. At BlueRock and AskBio, we're pursuing a two-pronged strategy for Parkinson's disease. It may be possible, for the first time ever, to halt and even reverse this degenerative condition and genuinely address the significant unmet medical needs of these patients. We're extremely proud to report that BlueRock has dosed its first Parkinson's patient with pluripotent stem cell-derived dopaminergic neurons in the phase I clinical study. Meanwhile, AskBio is advancing a gene therapy program built on adeno-associated virus, or AAV, which is actively enrolling and assessing patients in a phase I-B clinical trial that is ongoing. With these clinical trials underway, we're one step closer to the possibility of a truly breakthrough treatment that could dramatically improve life for people living with Parkinson's disease. Finally, we're also bolstering our drug discovery capabilities through the acquisition of Vividion Therapeutics. Vividion is a biopharmaceutical company headquartered in the U.S. that uses novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics. Vividion's technology leads the industry, and it has already demonstrated applicability pre-clinically in oncology and immune-related diseases, with potential to expand into other and additional therapeutic areas.
Werner Baumann
executiveOur modalities portfolio is already diversified thanks to our cell and gene therapy platform, and we keep feeding the pipeline with breakthrough innovation through the acquisition of Vividion. Stefan will be able to give further detail on the Vividion Therapeutics deal later during the Q&A. So with that, I'll now pass things over to Wolfgang.
Wolfgang Nickl
executiveThank you, Werner, and a warm welcome from me as well, ladies and gentlemen. I'll now take you through how our business performed in Q2 and the first half of the year, and then I'll cover our financial outlook for fiscal 2021. Just to note, whenever I refer to sales development, I mean numbers adjusted for portfolio and currency, unless I say otherwise. In Q2, our sales rose 13% to EUR 10.9 billion, and every one of our businesses delivered double-digit sales growth. Currency headwinds, however, hit sales to the tune of EUR 524 million. EBITDA before special items fell 11% year-on-year, landing at EUR 2.6 billion, with an adjusted EBITDA margin of 23.7%. Foreign exchange effects of EUR 153 million weighed heavily on that EBITDA before special items. The year-over-year swing in provisioning for variable compensation had a negative impact of EUR 467 million. I'll go into more detail on this shortly. We also faced higher costs of goods sold, particularly in pharma and Crop Science, and we invested in product launches, above all in pharma and Consumer Health. Core earnings per share in Q2 reached EUR 1.61. That's a 1% increase versus the prior year quarter, despite a negative foreign exchange effect of EUR 0.10.
Wolfgang Nickl
executiveThe shift in our core financial result, from minus EUR 343 million to minus EUR 115 million, contributed significantly to how core EPS performed. That came mostly from valuation gains on one of our Leaps investments, which completed a highly successful IPO in the quarter. For the quarter, our core tax rate was 24.4%, compared with 23.3% in the same quarter a year earlier. As we've guided, we still expect it to be around 23% for the full year. Earnings per share fell to minus EUR 1.48, driven mainly by special items of EUR 3.53, which relate primarily to the adjusted gross glyphosate provision of $4.5 billion, or EUR 3.8 billion, that we discussed last week. Non-cash impairment charges in our Crop Science division, net EUR 437 million, along with the usual adjustment for acquisition-related amortization, added EUR 1.04 to the decline. The tax effect was a positive EUR 0.56. The bridge from core EPS to reported earnings per share is in the appendix of our presentation. Free cash flow in the Q2 of 2021 came in at EUR 1.2 billion. That compares with EUR 1.4 billion a year earlier. A strong underlying cash flow profile was masked by litigation-related settlement payouts of about EUR 900 million.
Wolfgang Nickl
executiveAs is usual for us on a quarterly basis, net financial debt rose by EUR 428 million, reaching EUR 34.4 billion in Q2. Thanks to robust cash generation from operations and currency effects, that rise stayed quite modest, and those factors were largely able to offset the payment of dividends as well as litigation settlements. Now let's turn to H1 of the year, which in our view gives a better picture of how we performed once seasonality and pandemic-related dynamics are taken into account. Group sales rose an impressive 7%, to EUR 23 billion. Where earnings are concerned, though, our EBITDA margin — rather, our EBITDA before special items — fell by 8%. That decline stems chiefly from huge currency headwinds amounting to EUR 490 million and from higher provisions for variable compensation of EUR 534 million. This year-over-year swing effect weighed heavily on the bottom lines of the businesses and on the reconciliation. Since our performance is tied to growth, margins, core earnings per share and free cash flow, you'll remember that we cut our provision for variable compensation considerably last year because of the shortfalls related to the pandemic. As we already said in February, we would essentially restore our cost profile this year. Now, with the strong performance in H1 of the year and our improved outlook, we have raised that provision.
Wolfgang Nickl
executiveKeep in mind that Q2 is the quarter hit hardest, largely because of how seasonal this business is. Core earnings per share reached EUR 4.20, a modest decline of 1%, reflecting the EBITDA before special items effects described earlier, which a EUR 336 million improvement in our core financial results did not offset. For the first half, the core tax rate was 24.3%, versus 24% a year earlier. Free cash flow for H1 of 2021 dropped to minus EUR 2.1 billion, taking a heavy hit from net settlement payouts of roughly EUR 3.1 billion. Now I'd like to add some detail on how each of our three businesses performed in Q2. Crop Science posted double-digit sales growth of 11%, with every region contributing. Latin America and Asia Pacific stood out with significant gains, up 18% and 12%, respectively. North America, meanwhile, added the most in absolute terms, growing 10%. Within our strategic business entities, herbicides and fungicides drove growth during the quarter. Sales for our fungicide platform rose 23%, mainly on volume gains for Fox Xpro in Latin America plus new product launches in North America.
Wolfgang Nickl
executiveIn herbicides, we kept growing as well, with a 16% increase. Higher XtendiMax herbicide sales and Roundup price hikes in North America drove that gain. On insecticides, growth in Latin America and Asia Pacific wasn't enough to fully counter the hit from losing a thiacloprid registration in EMEA. In North America we maintained our number one spot in soybean weed control through our Xtend system, and our soybean seed and trait segments posted 9% sales growth. That North American growth came from volume, driven both by more acres planted and by the benefit of excess seed sales. Corn seed and traits likewise showed 9% sales growth, with gains across every region, most notably the Americas. Turning to earnings, EBITDA before special items fell sharply, down 25% to €1 billion, even with price increases and volume growth. Substantial negative currency effects of €111 million, an unfavorable sales mix and higher costs—chiefly in our COGS, with raw material and freight costs up—weighed on the bottom line. In our Pharma division, sales rose significantly, up 16% to €4.5 billion. Both of our blockbuster drugs, Eylea and Xarelto, kept up their strong performance. Eylea sales climbed 27%, reflecting robust demand in Europe after the prior-year quarter was heavily burdened by the COVID-19 pandemic's impact.
Wolfgang Nickl
executiveXarelto posted 13% growth, largely fueled by strong demand in China and Russia. When it comes to elective treatments, we gained substantially from the rebound after pandemic restrictions, since COVID-19 hit our year-ago quarter hard. That led the IUD franchise to climb 68%, while our radiology business rose 37%. Owing to the annualization of volume-based procurement effects on Glucobay and Avelox, plus robust Xarelto sales growth in China, sales increased 22%. The successful NUBEQA launch bolstered our Q2 performance, as Werner noted earlier. On the bottom line, launch investments, elevated COGS, higher incentive rules, and a negative currency impact of EUR 26 million were more than offset by strong sales growth, producing a 3% rise in EBITDA before special items. I'll wrap up the divisional update with Consumer Health. Our sales climbed significantly, by 13%, powered by growth across every region and category. Amid a market environment that remains volatile, we stay on our path of profitable growth by executing our strategy. The Nutritionals category kept up its strong growth momentum, rising 16% on sustained high demand. Allergy and Cold came back to growth after being hit hard by a weak flu season and ongoing COVID-19 related lockdown measures in earlier quarters that especially weighed on our cough and cold products.
Wolfgang Nickl
executiveFor this quarter, though, a robust allergy spring season across North America drove 16% growth in this category. North American growth was further boosted by the Avelox launch, which marked our entry into the topical pain treatment segment. Dermatology gained, among other things, from line extensions of Bepanthen in the dry skin segment, which grew 6% in Q2. All of these positive developments underscore how well balanced our category and geographical portfolio are. We lifted our clean EBITDA margin 50 basis points to 21.6%, thanks to strong sales growth and disciplined cost management, which clearly offset the impact from launch investments and negative currency effects amounting to EUR 20 million. Let's now move on and look at our guidance for the full year. As we outlined earlier, we saw a strong growth trajectory across the H1 of the year, with contributions from all three of our businesses. We're optimistic that the positive market environment in Crop Science and the good growth momentum for Pharma and Consumer Health will be sustained through the remainder of the year. So we are raising our guidance, even though the pandemic keeps increasing volatility in the markets. Please note that our guidance is based on constant currencies — put differently, average actual 2020 exchange rates.
Wolfgang Nickl
executiveIn the presentation, the light blue box shows what our outlook looks like at constant currency. The far-left column contains the full-year outlook that we provided in February. Immediately beside that, you'll find the guidance we have updated as of today. For group sales, we raised our guidance from the previous EUR 42 billion-EUR 43 billion to roughly EUR 44 billion now, and growth rates are higher across all businesses. At constant currencies, our EBITDA margin before special items is expected to land somewhat below what we guided in February, at 26%. For core EPS, we lifted our outlook, and we now anticipate core EPS between EUR 6.40 and EUR 6.60 at constant currencies. The earlier guidance we gave was EUR 6.10 to EUR 6.30. Should the highly favorable core financial result hold up through the rest of the year, we expect to hit the top end of that guidance. For the full year, we project keeping our core tax rate at roughly 23%. Our free cash flow guidance has been raised by EUR 1 billion, to a range of minus EUR 2 billion to minus EUR 3 billion, and that includes expected payouts of about EUR 7 billion for litigation settlements — EUR 1 billion less than we had anticipated back in February.
Wolfgang Nickl
executiveAs a result, we're raising our net financial debt guidance to roughly EUR 36 billion, compared with the EUR 36 billion to EUR 37 billion we had in February. I should note that Vividion Therapeutics' acquisition isn't included in this figure yet. In the gray box on the right, we show the currency impact for fiscal year 2021, using currencies at 2021 month-end June spot rates. The final column on the right shows our guidance at month-end June rates. We now anticipate a negative currency effect of only about EUR 1 billion on full year net sales, which largely came through in the H1 of the year. The effect on core EPS is around a negative EUR 0.40, which would take our outlook to between €6 and €6.20 at June month-end spot rates. The updated guidance for our businesses and other major KPIs is listed in the appendix of our investor deck. With that, I'll hand the call back to you, Oliver, so we can begin the Q&A, please.
Oliver Maier
executiveThanks, Wolfgang. And Werner, thanks for your comments. Emma, I believe we’re set to open the lines for questions now.
Operator
operatorOur first question is from Mr. Leuchten. Kindly give us your name and the company you represent, and then ask your question.
Michael Leuchten
analystThank you. This is Michael Leuchten from UBS. I'd like to begin with Crop Science and the absence of margin leverage, particularly since Q2 took a heavy hit from the STIs that you described. My first question: could you put a number on the input cost inflation pressure for us? How is that going to evolve in H2? And even more important, how much can you recover if 2022 turns out to be a normal year? On that same point, since 7% top-line growth at constant exchange rate leaves you with no more than a 24% EBITDA margin this year, how confident are you, given that consensus for the division sits at a 26% margin for 2022? A question on the equity ratio. In H1, that ratio came in under 27%. Where does it head from here, and what buffers exist? At what point would that ratio turn into a problem for you? My third question concerns Kerendia's positioning. Now that approval is in hand, I was hoping you could discuss your launch plans and how you'll segment the market, if possible. Thank you.
Oliver Maier
executiveOkay, Michael — thank you. So question one will go to Liam, then Wolfgang will handle the equity ratio, and after that Stefan will cover what we have planned for the Kerendia launch.
Speaker
unknownThanks so much, Michael. Perhaps I should begin with the final question you directed at me regarding how confident we are in the midterm targets — the 27%-29% EBITDA range we issued for 2024. I have a great deal of confidence in our capacity to hit those targets, and I'll attempt to lay that out now by providing some detail on what occurred in Q2 on the margin side, and why we feel strongly that we can deliver our guidance for 2021. I'll also shed a little light on some of the transitory impacts contained within that will give you a clearer picture of what might unfold going forward. When we break down Q2 at the margin impact on Crop Science, essentially three things are taking place there. The first is FX. If we simply set aside FX, which as mentioned comes to EUR 111 million, then two major components drive the margin decline. One is phasing effects, which I'll address, and the other relates to higher costs on product mix. Roughly half stems from phasing effects, and roughly half is tied to higher costs on product mix. Those phasing effects turn into positive effects during the H2 of the year.
Speaker
unknownI believe this first point really matters for understanding. What these phasing effects amount to is essentially this: you'll remember that last year, with the quite unusual COVID situation, we had very substantial seed returns and licensing true-ups in Q3 of 2020. This year, in a far more vibrant market environment, those true-ups have already come in Q2. That essentially lands on our Q2 result. It benefits our Q3 result, since we won't have those true-ups at that point. The second part is a shift in licensing income that last year arrived in Q2. This year it will arrive in Q3. Taken together, that is essentially half of the margin decline. It comes back in Q3. I just want to flag that to you very transparently. The other element, the remaining half, is a mixed bag of higher costs and product mix. On product mix, we flagged a little of this previously. We had lost an older corn license expiry, which carries a higher margin for us. We lost thiacloprid and neonicotinoid here in Europe registration, which is a high-margin product. This simply weighs to a degree on our margin, but of course it is a transitory effect, because you take that hit one time and not on an ongoing base.
Speaker
unknownThe increased costs really come down to two main pieces. The first is our short-term incentive, which Wolfgang mentioned — there's a swing compared with last year, since last year was very weak and this year we're projecting a much stronger overall performance by year-end. The second piece is partly a reversal of contingency spending. During COVID last year, we naturally hit the brakes on spending, as many companies did. We're not returning to the original spending levels, but we certainly are making some additional investments in R&D and on the commercial side, given that we're also steadily launching new products. There's something of a one-time effect in there. Again, this is a transitory impact. The larger portion of those costs was already incurred in H1 of the year rather than H2. The third element is COGS, and that's mostly material cost and freight. Here too, I think it's important to understand that much of our growth in H1 of the year came from heavy volumes, particularly herbicides and fungicides.
Speaker
unknownWhen it comes to seed production, we've got our production costs hedged. It's really the COGS on the crop protection side that carries more weight. As we move into the H2 of the year, pricing upside is going to be a much bigger driver of our growth. You'll see that across the board. Essentially, what you're going to see in the H2 of the year is a significantly higher margin than we had in the H2 of last year. That gives us confidence — a lot of confidence — that we can hit our 24% EBITDA guidance for this year on a constant currency base. Since many of those effects are transitory, you would expect margin lift going forward. That's why we're confident we can achieve our 27%-29% guidance range.
Wolfgang Nickl
executiveAlright, moving on to the equity ratio. Michael, hi, and thank you for that question. You're completely right. The equity ratio came down compared with Q1, going from 29% to 27%. By the way, at year-end it stood at 26%. In absolute figures, that's a move from roughly EUR 4 billion, from EUR 35 billion down to EUR 31 billion. Roughly half of that you can put down to the dividend we paid out. That, of course, comes straight out of equity. The remaining half reflects the reported loss, which is driven by the provision — the incremental provision we discussed last week. The balance sheet figure now sits at EUR 31 billion. I'm not worried. What matters even more than whether I'm worried or not is whether the rating agencies are worried. You can take it that, under NDA of course, we've spoken with them regarding the legal complex and also the exciting acquisition we announced today. You've seen Moody's already come out and confirm. I believe they do grasp that we are laser-focused on this. We feel we're in good shape on that front. We remain absolutely committed to net financial debt in 2024 of EUR 28 billion to EUR 30 billion. That brings a significant reduction in leverage. From that standpoint, I'm not worried, Michael.
Wolfgang Nickl
executiveI believe the next question was from Stefan, right?
Oliver Maier
executiveYeah, Stefan. That's right.
Stefan Oelrich
executiveHello, Michael, and thank you for that question. First, we are incredibly thrilled about the wide FDA label that Kerendia received after the agency's review — or, to be more exact, after the FDA's priority review. That label genuinely acknowledged the renal and cardiovascular outcomes seen in the pivotal FIDELIO-DKD trial. You asked specifically about the strategy for our launch, so let me perhaps start by noting that globally, over 160 million people are living with chronic kidney disease together with type two diabetes. That represents a major opportunity paired with a need that is even greater and still unmet. Kidney specialists are quite familiar with our mechanism of action. Until now, because of side effects, they had no medicine they could prescribe for this indication. We truly believe we now have the kidney medicine. By that I mean a product built to treat the kidney across five distinct indications. Let me remind you just how broad our label is and which indications it carries. We are indicated for lowering the risk of a sustained decline in eGFR. We are indicated in end-stage kidney disease to prevent cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure among adult patients who have CKD and Type 2 diabetes.
Stefan Oelrich
executiveThat's a really strong label. When you think about it, our initial push is going to focus specifically on nephrologists, endocrinologists, and a chosen set of primary care physicians. On top of that, we also have the FIDELIO data — you've already seen the top-line information on it — and it will be presented at the ESC meeting next month. I think the FIDELIO data, when pooled with the FIGARO data, really makes our case even stronger. We feel very good about this. The launch is underway now in the U.S. We should have a commercial presence in doctors' offices toward the end of this month. That's the start we're looking at.
Oliver Maier
executiveThanks.
Operator
operatorMr. Andrews, your line is next for a question. Kindly give us your complete name along with the name of your firm, and then go ahead with what you'd like to ask.
Vincent Andrews
analystHello, this is Vincent Andrews with Morgan Stanley. Liam, I was hoping you might share a bit more information about the Intacta 2 Xtend rollout in South America this fall — specifically, the price premium you've managed to secure relative to Intacta1, and whether your contractual capacity to raise prices in the years ahead, as necessary in response to foreign exchange or costs or anything else, has improved at all. In addition, what size launch are you expecting? Roughly over what timeframe do you believe Intacta2 can take the place of Intacta1?
Oliver Maier
executiveLiam?
Speaker
unknownYes. Thanks very much, Vincent. All our approvals are secured, and right now we're in the middle of ramping things up ahead of launch. With Intacta 2 Xtend, we're expecting to cover 600,000 acres this season. That's the starting target for this early launch phase. Naturally, the work we're doing — and the plan itself — is to move our Intacta franchise over to Intacta 2 Xtend as time goes on. As you're aware, with the Intacta franchise we sit at more than 85 million acres across Latin America. The potential here is tremendous. We've managed to strengthen the contractual setup on pricing, which, as you know from before, was tied solely to inflation. Apart from inflation, there was no way to raise prices. That is now being changed. For the launch phase, the first price bump over Intacta comes to roughly 5%. It's a mid-to-high single-digit lift — somewhere in the 5% to 8% range is what's in place for the initial launch phase at this point.
Vincent Andrews
analystAll right, let me just follow up on the U.S. season and how it unfolded. Looking at the corn and soy sales figures, it seems you achieved solid price realization in corn, which I suspect came more from cutting back on promotional spending than from adjusting list prices. How should we think about that as we head into next year, when I'd assume you'll face a fairly sizable rise in seed production costs? How confident are you that you'll be able to price well above that increase in production costs?
Speaker
unknownYeah. On corn, as you know, last season everyone had priced before commodity prices ran up. Now, in the new season, we have the chance to price again. We'll be issuing our price cards within the next two weeks — actually, by the end of August at the latest. Within August, we'll issue them. You can expect a significant price increase. This is U.S. corn I'm talking about. On the corn production side, we're actually hedged to a large degree. Our goal, from a pricing standpoint, is always that whatever increases occur in cost of goods, we pass them on to the market. That's just a basic philosophy of ours, and we're pretty rigorous about implementing it. You can expect to see a significant price increase going forward.
Vincent Andrews
analystGreat. We’ll be looking forward to it.
Operator
operatorOur following question is from Mr. Jackson. Kindly give us your name and the company you represent, then go ahead with your question.
Joel Jackson
analystHello there, and good afternoon. This is Joel Jackson from BMO. I'd like to spend a moment on crop protection pricing and how that ties into your efforts to push through the elevated costs you're facing. With inflation running higher, has it been simpler — or was it simpler — to pass along cost on lower-margin, cheaper items such as glyphosate? And when it comes to the pricier technologies within your crop protection portfolio, are you seeing a more competitive environment, one where passing off cost inflation through higher prices is tougher?
Speaker
unknownAllow me to add some detail here regarding CP pricing, and naturally, Joel, as you're aware, it varies considerably from one region to another. In fact, on the whole, we would anticipate passing along, once again, the higher COGS. We must transmit that to the market. The challenge, naturally, is that there's a delay between the moment we buy materials, run them through the entire manufacturing process and product inventory, and the point at which the product is sold — that built-in lag is simply something we have to manage, unlike, say, freight, which is instantly apparent to us. Broadly speaking, we've in fact witnessed quite robust price hikes for glyphosate, since you brought that up in particular. The price we charge for glyphosate is tightly tied to the cost of acid in China, which serves as something like the fundamental raw material for glyphosate. Owing to a supply shortage in China, that cost has risen substantially, and as a result, our market price for glyphosate has risen substantially too. We are highly flexible when it comes to pricing here. When the market price shifts, our price shifts, and we make adjustments quite regularly. In fact, we've already implemented several price increases during this season, and we anticipate additional ones even in the H2 of the year.
Speaker
unknownIn Latin America, as you know, the situation is somewhat different, since pricing there has to be done in local currency—though we aim to link it as closely as we can to movements in the U.S. dollar. On top of that, we typically implement several price increases over the course of the season. For instance, as we now head into the LatAm season, you should expect local price increases in the high single-digit range on the CP portfolio—that's what we'd anticipate. Overall, once again, we ought to be offsetting any rises in COGS as the year progresses. Given how crop protection works, there may be some time lag. Thus far we've managed to pass these through, or I think you'll see a greater pricing effect come through in the H2 of the year, again simply because of that time lag.
Joel Jackson
analystAll right. And last thing, do you anticipate any additional headwinds during the H2 of the year stemming from lost registrations?
Speaker
unknownNope. The major item in this year was thiacloprid, and we had already flagged that one last year since we knew it was on the way. Other than that, I wouldn't point to anything for the H2 of this year that's genuinely relevant. Thiacloprid's sales mostly fall in the H1 of the year rather than the H2.
Joel Jackson
analystI appreciate that.
Operator
operatorOur next question comes from Ms. Walton's line. Kindly give us your name and your company's name, and then ask your question.
Jo Walton
analystThank you. This is Jo Walton calling in from Credit Suisse. First, on the crop side, may I get some clarification: your underlying sales growth expectation has moved from 2% up to 7%. Does price account for the vast majority of that increase? Is any part of it tied to higher volume or to background improvement? Regarding that significant price improvement, is it simply that everyone is in a position to secure a price uplift, or are there areas where you're achieving it from a competitive standpoint? Turning to pharma, and again examining the raised sales guidance of 4%-6% in local currency, what share of that stems from COVID-related disruption returning, perhaps more quickly than you had anticipated, given very strong performance on the hospital imaging side? I'm not sure how sustainable that is, or whether it's simply a huge catch-up that won't persist going forward. Could you also update us on the NUBEQA rollout beyond Germany and how it is progressing. In the past you've stated that you would expect NUBEQA to reach your top 15 drugs by the end of this year. Does the same hold for neratinib? Thank you.
Speaker
unknownThanks so much, Jo. I'll take the first question. As you're aware, in the Crop Science business, the bulk of both sales and EBITDA comes in the first half of our year. Volume was up roughly 6% and price up 2% in that first half. That shifts as we move into the second half, when you'll see considerably more price increase than volume. How it all nets out by year-end, we'll find out. What's evident is that as time goes on, pricing's impact keeps building more and more toward the back end. Those price hikes clearly stem from a buoyant market, with corn and soybean commodity prices high. We must always price competitively, but the reality is that with our portfolio, in nearly every market, we're usually the price leader. A premium price is always our aim. When we raise prices, it often follows that others do the same. Overall, I think we've had a good market experience here, in that price increases don't necessarily mean we lose market share.
Speaker
unknownWhere market share lands really comes down to how the products perform in the market. On corn, across the board, we won't have the answer until the season wraps up, but it appears we've picked up some share. With soybeans, we're outperforming what we first anticipated, considering how fiercely competitive North America is. In crop protection, it's clear we think we're picking up share. Even with our premium pricing and the price increases we're putting through, I think there's still room for us to grow share as well.
Stefan Oelrich
executiveYeah. Hi, Jo. Regarding your question about performance versus catch-up versus real performance — obviously it's a blend of both, and I'd say that in H2 we're still going to see a bit of that catch-up as well. If I look at the underlying performance, some of the things I'd been telling all of you about over the past year — that while we were deep in the pandemic, with elective treatments lacking, we were gaining market share, particularly on EYLEA, and also in some of our women's healthcare business in the U.S. — that is now fully bearing fruit. With demand strong once more, the market share is coming through, and we're seeing that convert into growth. Part of this is performance. Let me also remind you that when we provided guidance for the year, when we guided for the 4%, every bit of the catch-up was already baked into that guidance. It was in there before. What also makes a significant difference is that VBP for Xarelto China arrived perhaps a little later than we had anticipated, and that gives us a bit of a lift as well for the rest of the year. On the NUBEQA rollout, we said the last time we spoke that it will reach the top 15 by the end of the year.
Stefan Oelrich
executiveWe stand by that. To reiterate, the top 15 is probably somewhere between EUR 200 million and EUR 250 million. Just to give you a sense, we're seeing really strong demand for NUBEQA in Q2 despite the pandemic. Across the board, we saw really strong reimbursement now in Germany, better than expected. This is going well. On finerenone, I wish I could tell you, but it's a little early to place this in the top 15 this year, because we're only basically coming out of the gate in September. I'm sure you will ask me a lot of questions on finerenone because you will have good visibility on demand with prescription data in the U.S.
Jo Walton
analystAppreciate it.
Operator
operatorOur following question is from Mr. Quigley. Kindly give us your name and your company's name, then ask your question.
James Quigley
analystHello there. Thank you for taking my question. This is James Quigley at Morgan Stanley. I have two, please, or perhaps two and a half. Regarding the Vividion acquisition, could you provide a bit more detail on this? How does it fit within the biodiscovery platform, what impact will it have on R&D costs on an annualized basis, and what margin drag will result from that? What is it about the platform that gives you confidence it will meaningfully improve your drug discovery capabilities? On eliapixant in the chronic cough indication, where do you believe it will be differentiated relative to Merck & Co.'s gefapixant? How do you plan to design the phase III trials? Are you considering any patient selection within those trials? As for the read across from the phase II that you reported yesterday or gave the top line on yesterday to the other indications, is there any, or is it more of a phase II taste for read across rather than anything else? Third one on Kerendia. What is the contracting situation like here and the reinvestment profile, or what are you expecting from a reinvestment profile in the U.S., or the trend of reinvestment? I think it was $19 a day price, which is obviously significantly more than the SGLT2s.
James Quigley
analystWhat kind of effect is that going to have on sales and on uptake? Thanks.
Stefan Oelrich
executiveAlright, thanks, James. Perhaps I'll start with Vividion. With this acquisition, I believe we're steadily delivering on our innovation vision and generating real value through breakthrough science. To us, Vividion is genuinely unique and, at the same time, a world-leading platform for tackling biological targets that nobody else has managed to tackle. It's 90% of all known disease-causing and disease-modifying proteins that we can now reach which previously were out of reach. Put another way, we're moving from the druggable era into the undruggable one, and that, I think, is an extraordinary leap. For us, it's the ideal fit. Our know-how in chemistry, and in drug development too, paired with Vividion, ought to genuinely unlock the full potential of this pioneering technology. You've seen their licensing deals, which I think were very noteworthy given the milestones tied to them that they concluded earlier, and how favorably this technology is viewed by some of our competitors as well. I think it's a tremendous step forward. On cost, we plan to absorb that within our overall R&D expense. Please don't treat it as an extra burden on our profile. Turning to eliapixant, I can't express how delighted I am with these results.
Stefan Oelrich
executiveMeanwhile, I’m not able to say precisely what that is, since we are awaiting the full data being published at a meeting that’s coming up. I can promise that when you see it, you will be just as delighted as I am right now. Regarding how we differ from Merck, you have observed strong efficacy with Merck. You have observed a side effect profile from them that is somewhat mixed. Keep watching, but my belief is that it will be a pleasant surprise. On finerenone’s entry with respect to price and reimbursement, naturally, we are currently prioritizing work with the various commercial payers in the U.S. so as to gain lives here. My view is that our price profile is quite favorable, because I believe you may be viewing this in the wrong way. Comparing us to SGLT2 as a price anchor isn’t necessarily appropriate, since this is not a diabetes drug. We are confident that our pricing is in fact right, and hopefully we will then also have—though it is too early to say—reasonable commercial conditions that permit not only solid uptake in prescriptions but also capture of the value we believe our medicine holds.
James Quigley
analystThanks a lot — that’s great.
Operator
operatorMr. Jones, your line is next. Kindly give us your name and the company you represent, then go ahead with your question.
Tony Jones
analystGood afternoon, everyone. This is Tony Jones calling from Redburn in London. I have three quick questions. Looking at slide 21, the pipeline, it indicates that SmartStax PRO is entering launch mode for next year. Could you share some detail on what the price premium could be, and perhaps some early-stage acreage estimates? Regarding litigation, when do you expect a decision on whether the Supreme Court takes the pre-emption case, or perhaps some kind of range? That would be very helpful. Returning to seeds, you mention being hedged. That appears rather Bayer-specific. Could you walk us through the mechanics of that, please, and explain how it works? Thank you.
Speaker
unknownThanks, Tony. I'll begin. SmartStax PRO launches next year, and at the start of the year we would in fact be providing guidance on it — how we view it from a one point standpoint. What you can expect, of course, is that it will carry a pricing premium relative to SmartStax. What we are observing, and also hearing frequently this year in the U.S. compared with the prior few years, is that corn rootworm pressure has increased. Our hope is that this arrives within a favorable market setting where we can achieve meaningful penetration. My suggestion would be that we bring you an update at that point, at the outset, when we issue our guidance for 2022, regarding the outlook specifically for that product litigation.
Oliver Maier
executivePerhaps you could handle the hedging on seeds as well.
Speaker
unknownYeah. Wolfgang, I’m not sure if you want to step in on the mechanics of how we handle hedging. Our fundamental approach, from a production standpoint, is that this isn’t an area where we’re looking to make a profit. What we really want is simply to avoid incurring losses. In essence, we hedge our soybean production and our corn production so that we can make sure there isn’t any excessive volatility in there. Not much else to add. That’s precisely why we do it.
Wolfgang Nickl
executiveAlright. We rely on standard derivatives. Yes, in order to do that. Tony, regarding your most recent question, we plan to submit our writ for the petition to the Supreme Court on August 23rd. That's only about two weeks away. After that, the Supreme Court could accept it on essentially any day. Typically, that process takes a good number of months. Our expectation is that around the turn of the year — end of 2021, early 2022 — by that point certainly, the Supreme Court will have decided whether to take the case or not, though it could also come sooner.
Tony Jones
analystThanks — that’s genuinely useful.
Operator
operatorOur following question is from Mr. Faitz. Kindly give us your name and your company's name, then ask your question.
Analyst
analystYes, thanks for taking my two questions, please. First, one for Liam, again, going back to the production cost — sorry about that. I appreciate that your seed production costs are hedged for this year on the seed side. What would that look like next year, and how much more expensive would that hedge be given the rise in crop commodity prices? Then, the second question is about the current heat drought wave in the Western U.S. Is that a concern for you? Are demand patterns affected in any way, let's say sprays in the Northwestern U.S. or veggie seeds in California? Thank you.
Speaker
unknownYeah. Thanks, Christian. Regarding production costs next year — and as you know, all of this hinges on where commodity prices sit — we could see somewhat higher hedging costs, but again, that fully depends on the overall commodity price level. With the peaks they're at right now, it's kind of hard to imagine this going significantly higher. I think we should be okay on that front. Just acoustically, I didn't really catch the second one — you meant the drought in California, whether that's impacting the veggies business?
Analyst
analystAnd the vegetables too, plus spraying out in the Northwestern U.S. — that region has been hit pretty hard. Could there be some kind of stockpiling effect when it comes to sprays that weren't put down? Anything along those lines.
Speaker
unknownYeah. For the farmers hit by this, it's obviously a terrible situation. We've also seen some pretty strange weather events in other regions of the world too. As for our business at the moment, we aren't seeing any meaningful effect. Our vegetables — and our fruit and vegetable business especially — is fairly specialized. A lot of what we do is indoor business as well. We aren't seeing anything that would make us overly worried right now. It is, obviously, for the farmers affected, a major problem. Regarding stocks in the channel, in North America in that particular case, we aren't noticing any elevated levels of inventory due to, say, mis-sprays. I think the only real issue is much further north than Canada and the continuing drought there, which probably, from a fungicide standpoint, is causing some higher inventories in the channel. On the whole, it isn't something that, at this moment, I would be materially concerned about in any way.
Analyst
analystAll right, that's great. Thank you, Liam. That was quite useful.
Oliver Maier
executiveEmma, I believe there's room for one or two additional questions. I'm watching the clock.
Operator
operatorAlright. Our final question comes from Mr. Parekh at Goldman. Kindly give us your name and the firm you represent, then ask your question. Go right ahead.
Analyst
analystHello, and good afternoon. Thanks for taking my questions. I have three, please. The first is for Liam. Liam, you gave a very eloquent explanation of the crop margin and how it varies between quarters, but my question is a bit different. You've moved from 2% top-line growth on crop at the beginning of this year to 7% top-line growth. There are very few businesses where growth more than doubles while margin expectations stay flat. I understand there are some things about this particular year that may be in question — how do you not drive greater margins when crop is growing 7%? Longer term, does this mean that 2024 and 2025 are now peak margins for this business, and that we need to start thinking more about volatility on the revenue line? That's question number one. Question number two is, if I read the disclosures correctly, your total employee compensation for the half is up 21% year-over-year. Your stock price is down 30% compared to the peer group over the last 12 months. Werner, I'm just keen on your thoughts about how you think about the various stakeholders in your business, and whether margin should flow through to your shareholders or to your employees. Lastly, on the call last week, Werner, you spoke about trying to rebuild trust in the intrinsic fundamental value of Bayer.
Analyst
analystIn no fewer than 6 of the past 12 quarters, some type of shortfall versus street expectations has occurred. On a quarterly basis, what is it that we are misjudging? Going forward, what can Bayer do to help us steer clear of those errors?
Speaker
unknownYes. Thank you very much. I’ll begin with the first question. I’ll do my best not to go over some of the points I explained before. Your question, at a high level, is whether 24% or 2024/2025 represents peak margin. I certainly don’t believe that’s the situation. As we entered this year, we described it as a transitional year. We provided specific guidance on the bottom line. We were aware that there would be some transitional effects, some transitory effects, which hit us mainly in the H1 of the year and ease in the H2 of the year and largely are absent next year. If you consider the position as we go into next year, when we ought to gain from some of the price increases coming through in the H2 of this year and from the efficiency measures, if we don’t face the transitory cost increase to the extent we did this year, then you should expect margin accretion. That’s what I would expect, and that’s why we are fully maintaining our midterm guidance of 27%-29%.
Werner Baumann
executiveOkay, I’ll address the remaining two questions, Liam. To begin with your first one: as you correctly note, compensation for our employees is up 21%. In a sense, that is somewhat a technicality and an artifact in the quarter, since we do have considerable volatility tied to Q2 of last year, with a significant baseline effect. Instead of establishing provisions for a normal-year bonus program, given the enormous COVID impact, it was already apparent that because of both COVID and FX, we would largely be out of the money, at least in 2 of our businesses. That actually produced a reversal of accruals into earnings. By contrast, this year, judging from where we began the year, we are, frankly, seeing improving momentum. We observe it across the board—on the top line and on the bottom line. We will certainly see some additional momentum—positive momentum—as we move into 2022. On that basis, you can see the year-over-year swing factor is over-expressed, and that has no bearing on a full-year employee or, let’s say, payroll structure that you would see by year-end. Second, when it comes to rebuilding trust, this is not about the receiver.
Werner Baumann
executiveOn the sender side, clearly we aren't getting this right. Last week, we aimed to give you complete transparency regarding where we intend to take the litigation and what the option space looks like that we provide for the, let's say, less favorable outcome on our balance sheet — so that you have full transparency — and we're trying to do the same today with our quarter, framing it around some of the effects that have been weighing on the quarter while at the same time giving you, I think, a bit more relevance, a full perspective, and full confirmation of where the year is going. Clearly, we have to do better. I fully accept that point.
Operator
operatorThat appears to be all the questions for now, Mr. Maier.
Oliver Maier
executiveAll right, excellent. Many thanks, Emma. We appreciate everyone joining us and giving us your time and focus today — it means a lot. That brings our call to an end. We'll speak with you again before long. Thanks.
Operator
operatorThat wraps up Bayer AG's Q2 2021 conference call for investors and analysts. Thanks for taking part, everyone. You're free to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Bayer Aktiengesellschaft transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Bayer Aktiengesellschaft earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Bayer Aktiengesellschaft or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.